Skip to main content
SpringerLink
Log in

Possible anti-metastatic effect of Iloprost in a patient with systemic sclerosis with lung cancer: a case study

  • Short Communication
  • Published:
Rheumatology International Aims and scope Submit manuscript

Abstract

Systemic Sclerosis (SSc) is a chronic disease of unknown etiology which affects the vascular system and connective tissue. A wide series of studies showed an increased prevalence of cancer in patients with SSc than the normal population. Prostacyclin (PGI2) is an endogenously produced element that is basically synthesized by arachiodonic acid through prostacyclin synthesis in vascular system endothelial cells. Iloprost is a stable analogue of PGI2 which is used in the treatment of pulmonary arterial hypertension (PAH). In a limited number of animal models, the anti-metastatic activity of PGI2 is observed. Herein, we report iloprost treatment of a 60-year-old-woman with SSc, who lately developed PAH as a complication of her disease and lung adenocarcinoma as a co-incidence simultaneously. These two mortal complications were both treated successfully with inhaled iloprost until her death due to gastrointestinal complications of SSc.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

References

  1. Gilliland BC (2005) Systemic sclerosis and related disorders. In: Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL (eds) Harrison principles of internal medicine, 6th edn. New York, Mc Graw-Hill, pp 1979–1990

    Google Scholar 

  2. Abu-Shakra M, Guillemin F, Lee P (1993) Cancer in systemic sclerosis. Arthritis Rheum 36:460–464

    Article  PubMed  CAS  Google Scholar 

  3. Yang Y, Fujita J, Tokuda M, Bandoh S, Ishida T (2001) Lung cancer associated with several connective tissue diseases: with a review of literature. Rheumatol Int 21:106–111

    Article  PubMed  CAS  Google Scholar 

  4. Goldsmith DR, Wagstaff A (2004) Inhaled iloprost in primary pulmonary hypertension. Drugs 64:763–773

    Article  PubMed  CAS  Google Scholar 

  5. Scott JP, Higenbottam T, Wallwork J (1990) The acute effect of synthetic prostacyclin analogue iloprost in primary pulmonary hypertension. Br J Clin Pract 44:231–234

    PubMed  CAS  Google Scholar 

  6. Black CM (1995) The aetiopathogenesis of systemic sclerosis: thick skin-thin hypotheses. The parkes weber lecture. J R Coll Physicians Lond 29:119–130

    PubMed  CAS  Google Scholar 

  7. Siau K, Laversuch CJ, Creamer P, O’Rourke KP (2010) Malignancy in scleroderma patients from south west England: a population-based cohort study. Rheumatol Int. 8. [Epub ahead of print]

  8. Chatterjee S, Dombi GW, Severson RK, Mayes MD (2005) Risk of malignancy in scleroderma. A population-based cohort study. Arthritis Rheum 52:2415–2424

    Article  PubMed  Google Scholar 

  9. Moncada S, Gryglewski R, Bunting S, Vane JR (1976) An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 263:663–665

    Article  PubMed  CAS  Google Scholar 

  10. Belch JJ (1987) Effect of iloprost (ZK 36374) on white cell behaviour. In: Gryglewski RJ, Stock G (eds) Prostacyclin and its stable analogue iloprost. Springer-Verlang, Berlin- Heidelberg, pp 97–102

    Chapter  Google Scholar 

  11. Stürzebecher CS (1987) Effects of iloprost on platelet activation in vitro. In: Gryglewski RJ, Stock G (eds) Prostacyclin and its stable analogue iloprost. Springer, Berlin-Heidelberg, pp 39–45

    Chapter  Google Scholar 

  12. Wigley FM, Wise RA, Seibold JR, McCloskey DA, Kujala G, Medsger TA Jr, Steen VD, Varga J, Jimenes S, Mayes M (1994) Inrtavenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sklerosis. A multicenter, placebo-controlled, double-blind study. Ann Intern Med 120:199–206

    PubMed  CAS  Google Scholar 

  13. Gasic GJ (1984) Role of plasma, platelets and endothelial cells in tumour metastasis. Cancer Metastasis Rev 3:99–116

    Article  PubMed  CAS  Google Scholar 

  14. Honn KV, Cicone B, Skoff A (1981) Prostacyclin: a potent antimetastatic agent. Science 212:1270–1272

    Article  PubMed  CAS  Google Scholar 

  15. Sava G, Perisin L, Zorzet S, Piccini P, Giraldi T (1989) Antimetastatic action of the prostacyclin anologue Iloprost in the Mouse. Clinical and Experimental Meastasis 7:671–678

    Article  CAS  Google Scholar 

  16. Schirner M, Schneider MR (1991) Cicaprost inhibits metastases of animal tumours. Prostaglandins 42:451–461

    Article  PubMed  CAS  Google Scholar 

  17. Menter DG, Onoda JM, Taylor JD, Honn KV (1984) Effect of prostacyclin on tumour cell-induced platelet aggregation. Cancer Res 44:450–456

    PubMed  CAS  Google Scholar 

  18. Tang DG, Grossi IM, Tang KQ, Diglio CA, Honn KV (1995) Inhibition of TPA and 12(S)-HETE-stimulated tumour cell adhesion by prostacyclin and its stable analogs: rationale for their antimetastatic effects. Int J Cancer 60:418–425

    Article  PubMed  CAS  Google Scholar 

  19. Schneider MR, Schillinger E, Schirner M, Skuballa W, Stürzebecher S, Witt W (1991) Effects of prostacyclin analogues in in vivo tumour models. Adv Prostaglandin Thromboxane Leukot Res 21:901–908

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. School of Medicine, Departments of Rheumatologyn, Sahinbey Medical Center, Gaziantep University, TR-27310, Gaziantep, Turkey

    Yavuz Pehlivan & Ahmet Mesut Onat

  2. School of Medicine, Departments of Internal Medicine, Sahinbey Medical Center, Gaziantep University, TR-27310, Gaziantep, Turkey

    Ibrahim Halil Turkbeyler

  3. School of Medicine, Departments of Medical Oncology, Gaziantep Oncology Hospital, Gaziantep University, TR-27310, Gaziantep, Turkey

    Ozan Balakan & Alper Sevinc

  4. School of Medicine, Departments of Nukleer Medicine, Gaziantep Oncology Hospital, Gaziantep University, TR-27310, Gaziantep, Turkey

    Mustafa Yilmaz

  5. School of Medicine, Departments of Pathology, Sahinbey Medical Center, Gaziantep University, TR-27310, Gaziantep, Turkey

    Kemal Bakir

Authors
  1. Yavuz Pehlivan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ibrahim Halil Turkbeyler
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ozan Balakan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Alper Sevinc
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mustafa Yilmaz
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kemal Bakir
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ahmet Mesut Onat
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yavuz Pehlivan.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pehlivan, Y., Turkbeyler, I.H., Balakan, O. et al. Possible anti-metastatic effect of Iloprost in a patient with systemic sclerosis with lung cancer: a case study. Rheumatol Int 32, 1437–1441 (2012). https://doi.org/10.1007/s00296-011-1848-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-011-1848-4

Keywords

Search

Navigation